These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24256258)

  • 21. The endocannabinoid system in targeting inflammatory neurodegenerative diseases.
    Centonze D; Finazzi-Agrò A; Bernardi G; Maccarrone M
    Trends Pharmacol Sci; 2007 Apr; 28(4):180-7. PubMed ID: 17350694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidative stress signalling in Alzheimer's disease.
    Zhu X; Raina AK; Lee HG; Casadesus G; Smith MA; Perry G
    Brain Res; 2004 Mar; 1000(1-2):32-9. PubMed ID: 15053949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocannabinoids in the immune system and cancer.
    Parolaro D; Massi P; Rubino T; Monti E
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):319-32. PubMed ID: 12052046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer's disease.
    Polidori MC; Griffiths HR; Mariani E; Mecocci P
    Amino Acids; 2007; 32(4):553-9. PubMed ID: 17273806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating Endocannabinoids in Canine Multicentric Lymphoma Patients.
    Hay JK; Hocker SE; Monteith G; Woods JP
    Front Vet Sci; 2022; 9():828095. PubMed ID: 35242839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocannabinoid system and mood disorders: priming a target for new therapies.
    Micale V; Di Marzo V; Sulcova A; Wotjak CT; Drago F
    Pharmacol Ther; 2013 Apr; 138(1):18-37. PubMed ID: 23261685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wnt signaling in the nervous system and in Alzheimer's disease.
    Inestrosa NC; Varela-Nallar L
    J Mol Cell Biol; 2014 Feb; 6(1):64-74. PubMed ID: 24549157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer's disease.
    Jayasena T; Poljak A; Smythe G; Braidy N; Münch G; Sachdev P
    Ageing Res Rev; 2013 Sep; 12(4):867-83. PubMed ID: 23831960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocannabinoid system: An overview of its potential in current medical practice.
    Mouslech Z; Valla V
    Neuro Endocrinol Lett; 2009; 30(2):153-79. PubMed ID: 19675519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammation and neurodegeneration: the story 'retolled'.
    Drouin-Ouellet J; Cicchetti F
    Trends Pharmacol Sci; 2012 Oct; 33(10):542-51. PubMed ID: 22944460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease.
    Blass JP; Gibson GE
    Rev Neurol (Paris); 1991; 147(6-7):513-25. PubMed ID: 1962057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications.
    Onaivi ES
    Int Rev Neurobiol; 2009; 88():335-69. PubMed ID: 19897083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum endocannabinoid levels in suicide attempters: A pilot study.
    Herranz-Herrer J; Gil-Benito E; Ponte-López T; Ortega-Gutiérrez S; Macicior J; Rosado-Garcia S; Sánchez-López AJ; Blasco-Fontecilla H
    Eur Neuropsychopharmacol; 2020 Nov; 40():52-60. PubMed ID: 32994115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders.
    Assogna M; Di Lorenzo F; Martorana A; Koch G
    Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabinoids in late-onset Alzheimer's disease.
    Ahmed A; van der Marck MA; van den Elsen G; Olde Rikkert M
    Clin Pharmacol Ther; 2015 Jun; 97(6):597-606. PubMed ID: 25788394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered hair endocannabinoid levels in mothers with childhood maltreatment and their newborns.
    Koenig AM; Gao W; Umlauft M; Schury K; Reister F; Kirschbaum C; Karabatsiakis A; Kolassa IT
    Biol Psychol; 2018 May; 135():93-101. PubMed ID: 29567268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential and Limits of Cannabinoids in Alzheimer's Disease Therapy.
    Abate G; Uberti D; Tambaro S
    Biology (Basel); 2021 Jun; 10(6):. PubMed ID: 34204237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The endocannabinoid system: 'NO' longer anonymous in the control of nitrergic signalling?
    Lipina C; Hundal HS
    J Mol Cell Biol; 2017 Apr; 9(2):91-103. PubMed ID: 28130308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploring the Utility of Hair Endocannabinoids for Monitoring Homeostasis in Bonobos.
    Behringer V; Krumbholz A; Stevens JMG; Keiler AM; Zierau O; Hohmann G
    Physiol Biochem Zool; 2021; 94(2):83-98. PubMed ID: 33434116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer's Disease.
    Beggiato S; Tomasini MC; Ferraro L
    Front Pharmacol; 2019; 10():821. PubMed ID: 31396087
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.